Trends in tuberculosis – is a different problem emerging?
DOI:
https://doi.org/10.3126/ajms.v15i11.69170Keywords:
Drug resistance; GeneXpert CBNAAT; Mycobacterium tuberculosis; People living with human immunodeficiency viruses; Tuberculosis incidenceAbstract
Background: Tuberculosis (TB), as a communicable disease, is an ongoing global epidemic that accounts for a high burden of global mortality and morbidity. Drug-resistant TB strains are one of the hurdles in controlling TB problem. TB is the most common opportunistic infection in people living with human immunodeficiency viruses (PLHIV). To accelerate progress toward the goal of ending TB by 2035, it is imperative to outline the incidence and mortality trends of TB in India.
Aims and Objectives: This study aims to provide deep insights into the recent trends of TB incidence and mortality in India from 2018 to 2023.
Materials and Methods: This is a cross-sectional type of observational study done, over a period of 6 years from 2018 to 2023. It included 21,223 suspected samples tested for TB and rifampicin (rif) resistance with GeneXpert CBNAAT (cepheid) for infection of Mycobacterium tuberculosis (MTB).
Results: Out of total 21,223 samples tested, 17.97% of samples were positive for MTB. From the year 2018 to 2023, 9.5% decline was seen in overall TB cases. However, the diagnosis of rif resistance is in similar range for all the study years. New patients show slight decline, but previous patients show higher rif resistance. There is decreased TB incidence in PLHIV.
Conclusion: Overall, the incidence of TB has decreased in the past 6 years. The acquired drug resistance was seen in 32.6% cases. The study found an overall decrease in the incidence of TB in PLHIV.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
